SCHEMBL2968944

SCHEMBL2968944

Cc1ccc(Sc2ccc(F)cc2)c(Nc2ccnc3nc(C)ccc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
AKT2 P31751 1/20 0.39
HTR1A P08908 3/20 0.36
HTR3A P46098 2/20 0.36
BLM P54132 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
PKM P14618 1/20 0.32
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
TGFBR1 P36897 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968986 0.93 PIM1 (0.41) PIM1AKT2HTR1AHTR3ABLM
SCHEMBL2022784 0.89 PIM1 (0.39) PIM1AKT2HTR1AADRA1DADRA1A
SCHEMBL2015588 0.89 PIM1 (0.49) PIM1AKT2HTR1AMEN1NPC1
SCHEMBL2018796 0.89 PIM1 (0.42) PIM1AKT2HTR1AHTR3AMEN1
SCHEMBL13273744 0.89 PIM1 (0.38) PIM1AKT2CCNCCDK8TGFBR1
SCHEMBL2962035 0.87 PIM1 (0.43) PIM1AKT2HTR1AHTR3AMEN1
SCHEMBL2970305 0.86 PIM1 (0.38) PIM1AKT2HTR1AHTR3AADRA1D
SCHEMBL2961106 0.85 PIM1 (0.44) PIM1AKT2HTR1AMEN1NPC1
SCHEMBL2964962 0.85 PIM1 (0.39) PIM1AKT2BLMKDM4EMAPT
SCHEMBL2961202 0.85 PIM1 (0.39) PIM1AKT2BLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
CN-101384592-A Antiviral compounds ABBOTT LAB (US) 2009-03-11 CN disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885HTR1A 4760/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885HTR1A 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.